Update on treatment of pulmonary exacerbations in cystic fibrosis

被引:25
作者
Smyth, Alan [1 ]
机构
[1] City Hosp Nottingham, Div Resp Med, Nottingham MG5 1PB, England
关键词
cystic fibrosis; Pseudomonas aeruginosa; pulmonary exacerbations;
D O I
10.1097/01.mcp.0000245711.43891.16
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Purpose of review This review will define pulmonary exacerbations in cystic fibrosis and explain their importance in the pathophysiology and progression of this condition. I will stress the importance of prevention, where this is possible, and prompt treatment, where prevention has failed. The management of chronic pulmonary infection with Pseudomonas aeruginosa will be discussed, together with other, less tenacious organisms. Recent findings Developments in the treatment of chronic pulmonary infection with P. aeruginosa include new data on antibiotic selection through sensitivity testing and alternative antibiotic dosing regimens. Therapies which target the P. aeruginosa biofilm will be discussed, including those which are currently in use (such as azithromycin) as well as those being evaluated in preclinical studies. Supportive care and the role of noninvasive ventilation are discussed. Summary The prevention and prompt treatment of pulmonary exacerbations is a central component of cystic fibrosis care.
引用
收藏
页码:440 / 444
页数:5
相关论文
共 41 条
[1]   Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa [J].
Aaron, SD ;
Ramotar, K ;
Ferris, W ;
Vandemheen, K ;
Saginur, R ;
Tullis, E ;
Haase, D ;
Kottachchi, D ;
St Denis, M ;
Chan, F .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 169 (07) :811-815
[2]   Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial [J].
Aaron, SD ;
Vandemheen, KL ;
Ferris, W ;
Fergusson, D ;
Tullis, E ;
Haase, D ;
Berthiaume, Y ;
Brown, N ;
Wilcox, P ;
Yazghatlian, V ;
Bye, P ;
Bell, S ;
Chan, F ;
Rose, B ;
Jeanneret, A ;
Stephenson, A ;
Noseworthy, M ;
Freitag, A ;
Paterson, N ;
Doucette, S ;
Harbour, C ;
Ruel, M ;
MacDonald, N .
LANCET, 2005, 366 (9484) :463-471
[3]   Alginate lyase enhances antibiotic killing of mucoid Pseudomonas aeruginosa in biofilms [J].
Alkawash, MA ;
Soothill, JS ;
Schiller, NL .
APMIS, 2006, 114 (02) :131-138
[4]  
*ANT CONS GROUP, 2002, ANT TREATM CYST FIBR
[5]   Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis [J].
Balfour-Lynn, Ian M. ;
Lees, Belinda ;
Hall, Pippa ;
Phillips, Gillian ;
Khan, Mohammed ;
Flather, Marcus ;
Elborn, J. Stuart .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 173 (12) :1356-1362
[6]  
BHALLA P, 2000, COCHRANE DB SYST REV, V1
[7]   Garlic blocks quorum sensing and promotes rapid clearing of pulmonary Pseudomonas aeruginosa infections [J].
Bjarnsholt, T ;
Jensen, PO ;
Rasmussen, TB ;
Christophersen, L ;
Calum, H ;
Hentzer, M ;
Hougen, HP ;
Rygaard, J ;
Moser, C ;
Eberl, L ;
Hoiby, N ;
Givskov, M .
MICROBIOLOGY-SGM, 2005, 151 :3873-3880
[8]   The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis [J].
Blumer, JL ;
Saiman, L ;
Konstan, MW ;
Melnick, D .
CHEST, 2005, 128 (04) :2336-2346
[9]   Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients [J].
Cantón, R ;
Cobos, N ;
de Gracia, J ;
Baquero, F ;
Honorato, J ;
Gartner, S ;
Alvarez, A ;
Salcedo, A ;
Oliver, A ;
García-Quetglas, E .
CLINICAL MICROBIOLOGY AND INFECTION, 2005, 11 (09) :690-703
[10]   In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis [J].
Chen, YH ;
Garber, E ;
Zhao, QQ ;
Ge, YG ;
Wikler, MA ;
Kaniga, K ;
Saiman, L .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (06) :2510-2511